Scholar Rock Holding Co. (NASDAQ:SRRK) Receives Average Rating of "Buy" from Analysts

Scholar Rock Holding Co. (NASDAQ:SRRK - Get Free Report) has earned a consensus recommendation of "Buy" from the six research firms that are presently covering the firm, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $42.67.

Separately, Wedbush reissued an "outperform" rating and set a $50.00 price target on shares of Scholar Rock in a research note on Tuesday, March 25th.

Insiders Place Their Bets

In related news, Director Katie Peng sold 1,006 shares of the company's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $34.42, for a total value of $34,626.52. Following the completion of the sale, the director now owns 30,319 shares in the company, valued at $1,043,579.98. This represents a 3.21 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Tracey Sacco sold 6,500 shares of Scholar Rock stock in a transaction dated Monday, March 24th. The stock was sold at an average price of $33.08, for a total value of $215,020.00. Following the transaction, the insider now owns 71,750 shares in the company, valued at approximately $2,373,490. This represents a 8.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 299,772 shares of company stock worth $11,245,798. Insiders own 19.20% of the company's stock.

Institutional Investors Weigh In On Scholar Rock

Hedge funds have recently modified their holdings of the business. Wellington Management Group LLP grew its position in shares of Scholar Rock by 16.2% in the 3rd quarter. Wellington Management Group LLP now owns 199,777 shares of the company's stock valued at $1,600,000 after purchasing an additional 27,801 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in Scholar Rock by 9.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 502,793 shares of the company's stock valued at $4,027,000 after buying an additional 42,139 shares in the last quarter. Barclays PLC boosted its holdings in shares of Scholar Rock by 103.4% in the third quarter. Barclays PLC now owns 165,449 shares of the company's stock valued at $1,324,000 after buying an additional 84,118 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Scholar Rock by 7.1% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 94,795 shares of the company's stock worth $759,000 after acquiring an additional 6,269 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Scholar Rock by 8.5% during the third quarter. Geode Capital Management LLC now owns 1,543,025 shares of the company's stock worth $12,361,000 after acquiring an additional 120,489 shares during the period. Institutional investors and hedge funds own 91.08% of the company's stock.

Scholar Rock Trading Up 6.4 %

NASDAQ:SRRK traded up $1.69 on Monday, hitting $28.00. 1,761,907 shares of the stock were exchanged, compared to its average volume of 1,215,842. The company has a debt-to-equity ratio of 0.63, a quick ratio of 3.88 and a current ratio of 3.88. Scholar Rock has a 52 week low of $6.76 and a 52 week high of $46.98. The stock has a market capitalization of $2.65 billion, a price-to-earnings ratio of -11.91 and a beta of 0.56. The company's 50-day moving average price is $34.21 and its 200 day moving average price is $34.51.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.